Amphastar Pharmaceuticals, Inc. (AMPH)

Market Cap	2.26B
Revenue (ttm)	712.89M
Net Income (ttm)	166.52M
Shares Out	48.68M
EPS (ttm)	3.15
PE Ratio	14.74
Forward PE	11.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	80,341
Open	46.97
Previous Close	46.83
Day's Range	46.26 - 47.31
52-Week Range	36.56 - 65.92
Beta	0.83
Analysts	Buy
Price Target	63.00 (+35.85%)
Earnings Date	Nov 6, 2024

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection eme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2014
• Employees: 1,761
• Stock Exchange: NASDAQ
• Ticker Symbol: AMPH
• Website: https://www.amphastar.com

Financial Performance

In 2023, Amphastar Pharmaceuticals's revenue was $644.40 million, an increase of 29.14% compared to the previous year's $498.99 million. Earnings were $137.55 million, an increase of 50.51%.

Analyst Forecast

According to 4 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $63.0, which is an increase of 35.85% from the latest price.

Price Target

$63.0

(35.85% upside)

Analyst Consensus: Buy